Our Technology

Innovative Protein Therapies


Darnatein leverages a unique synthetic biology platform enhanced by design-augmented AI to create novel protein chimeras with superior efficacy compared to their natural parent ligands. The company is currently focused on engineering improved BMPs (Bone Morphogenetic Protein), key proteins involved in bone and cartilage healing. Existing BMP drugs require high doses, which can lead to significant local and systemic side effects. In contrast, Darnatein’s DA-BMPs are designed for greater therapeutic potency, enabling lower dosing and reducing the risk of adverse events.


- Natural proteins require high doses in therapeutic setting, causing side effects.

- Darnetein's technolgy platform combines activities of known BMP family members into new constructs with superior activity and efficacy.
- Targeted protein design enhances efficacy but maintains low immuogenicity of the natural endogenous proteins. 

- Integration of AI-augmented design affords scope for further improvement and access to novel targets.


- DRT-102: design-augmented BMP-2/Activin chimeric protein for bone fusion
- DRT-101: design-augmented BMP-7/Activin chimeric protein for regneration




 Vision


Cares about people and health

Under the slogan ‘A Company That Cares for People and Health,’ we are accelerating the development of therapeutics, starting with treatments for musculoskeletal disorders and expanding into therapies for target diseases such as diabetes and obesity. The Biologics sector is a rapidly growing field worldwide, with an average annual market growth of over 20%. Compared to synthetic drugs, biologics have already been recognized in both academia and industry as more effective for treating severe diseases, with fewer side effects and greater safety.


Management


Management Philosophy and Management Goals

Mechanism of Action


Privacy Policy  I  Terms of Service
Copyright ⓒ Darnatein All rights reserved.